Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hereditary breast cancer: clinical, pathological and molecular characteristics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Subtypes in BRCA-mutated breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Troels Dreier Christensen
  • Anna Sofie Kappel Buhl
  • Ib Jarle Christensen
  • Ida Kappel Buhl
  • Eva Balslev
  • Ann S Knoop
  • Hella Danø
  • Vesna Glavicic
  • Adam Luczak
  • Sven Tyge Langkjer
  • Søren Linnet
  • Erik Hugger Jakobsen
  • Jurij Bogovic
  • Bent Ejlertsen
  • Annie Rasmussen
  • Anker Hansen
  • Steen Knudsen
  • Peter Buhl Jensen
  • Dorte Nielsen
Vis graf over relationer

BACKGROUND: Fulvestrant is a selective oestrogen receptor (ER) degrader used as monotherapy and combination therapy for ER positive HER2 negative advanced breast cancer (ABC) in postmenopausal women. The drug response predictor (DRP), is a mathematical algorithm based on the expression of multiple genes in the tumour. The fulvestrant DRP algorithm has previously shown effect in BC. In this study, we investigated the DRP's potential in predicting fulvestrant benefit.

METHOD: Among 695 patients with ABC prospectively included in a Danish Breast Cancer Cooperative Group (DBCG) cohort we retrospectively included 226 patients who received fulvestrant as monotherapy. The DRP result was based on mRNA extracted from tumour biopsies and analysed using Affymetrix array. Primary endpoint was time to progression (TTP).

RESULTS: For patients who received fulvestrant in line one to four and were previously unexposed to adjuvant endocrine therapy, we identified a hazard ratio (HR) of 0.44 (90% confidence interval (90% CI) upper limit of 1.08, one sided p = 0.066) for a predicted positive vs negative outcome. A weaker association was seen when including patients exposed to adjuvant endocrine treatment or received fulvestrant in fifth or later lines. Exploratory analyses showed that the DRP was efficient when using recent biopsies for DRP estimate and among recently treated patients.

CONCLUSION: The DRP showed a potential in predicting fulvestrant treatment but was not significant in the overall analysis. Use of older biopsies, long-term endocrine treatment and multiple therapies between biopsy used for analysis and fulvestrant treatment, probably affect the predictive accuracy.

OriginalsprogEngelsk
TidsskriftBreast Cancer: Basic and Clinical Research
ISSN1178-2234
DOI
StatusE-pub ahead of print - 25 okt. 2019

ID: 58227231